MAIA gets an FDA approval on cancer drug

The company also went public last week, raising nearly $10 million in its initial public offering as it hopes to revolutionize cancer treatment.

Previous Bison Wealth is Pegulas’ latest business venture
Next Adventist Health trims administrative staff, cuts 52 positions at Roseville headquarters